The Innovative Therapies Days will make the connection between the academic and the industrial worlds: from research, to clinical trials, to industrialization.
CAR-T CELLS
Chimeric antigen receptor T cell (CAR-T) therapy has revolutionized the revolutionized the disease course of patients with refractory/resistant refractory/resistant hematological malignancies. Based on these these unexpected and impressive results, the world of immunotherapy cellular immunotherapy offers new perspectives.
This session will cover a wide range of topics from research to understand mechanisms, production with alternative cell sources, to the clinic with feedbacks from the specific Spanish and from the productive Chinese models. Clinical management of innovative drugs in real life will also be discussed.
Mixing and exchanges of people from different backgrounds (academics, scientists, pharmacists, clinicians, mature and young biotech companies…) will provide an excellent platform to help the development of CAR-T cells in France and worldwide in order to propose these innovative drugs to patients.
RNA is the basis for numerous therapeutic product manufacturing. Biologics, recombinant proteins, gene-modified cells, vaccines… all of these innovative therapies are somehow dependent on RNA. This session will cover different aspects of RNA manufacturing and applications in several settings like vaccines and biologics.
This session will gather experts in the development of new cell therapies to the clinic.
Speakers will give us feedback on difficulties and successes, and their view on the future of such approaches to ameliorate patients’ care.
This session will give exemples of the ATMP production ecosystem, with pre-industrial and industrial structures, and the challenges of financing these therapies.
We will also have a presentation of the regulatory guidelines defined for ATMPs and the new European regulation on clinical trials, by the European Medicines Agency and by the CAT (French Committee for Advanced Therapy Products).
Introductive words, Dr Sylvain Perruche, RIGHT Institute, Besançon, FR
Welcome words from the urban community’s President and the Region’s President
Introduction by Dr Marco Ruella, UPENN, Philadelphia, USA
Chairmen: Dr Christophe Ferrand and Dr Marina Deschamps, RIGHT Institute, Besançon, FR
Dr Philippe Bousso, Institut Pasteur and Inserm, Paris, FR
Dr Julien Valton, Cellectis, Paris, FR
Pr Huang He, Bone Marrow Transplantation Center and Institute of Hematology , Zhejiang University, Hangzhou , PRC
Dr Álvaro Urbano Ispizua, Hospital Clínic de Barcelona, SP
Pr Roch Houot, UMR INSERM U1236, Rennes, FR
Chairmen: Dr Sylvain Perruche, RIGHT Institute, Besançon, FR
Pr Olivier Detante, Grenoble Institute of Neuroscience, Grenoble, FR
Eric Halioua, PDC*line Pharma, Liège, BE
Dr Nathalie Labarriere , INCIT, UMR 1302, Nantes, FR
Dr Omid Veiseh, Rice University, Houston, USA
Dr Miguel Forte, ISCT, Charleroi, BE
WEDNESDAY, SEPTEMBER 21ST
Chairwoman: Dr Mathilde Girard, ADHARA, subsidiary of the URGO Group, Chenôve, and Dr Mathieu Guerriaud, CREDIMI, Dijon, FR
Emmanuel DEQUIER, « Grand défi Biomedicaments », Secrétariat Général pour l’Investissement, Paris, FR
Andreas Wallnöfer, Jeito Capital, Paris, FR
Dr Claire Gérard, Agence nationale de sécurité du médicament et des produits de santé (ANSM), Lyon, FR
Dr Mathieu Guerriaud, CREDIMI, Dijon, in collaboration with Pr Evelyne Kohli, INSERM LNC-UMR1231, Dijon, FR
Dr Céline Elie-Caille, FEMTO-ST Institute, Besançon, FR
Chairman : Dr Philippe DULIEU, RD Biotech, Besançon, FR ; and Pr Olivier ADOTEVI, RIGHT Institute, Besançon, FR
Pr Chantal Pichon, Center for Molecular Biophysics -UPR4301 CNRS, Orléans, FR
Dr Marco Alessandrini, Antion Biosciences, Geneva, CH
Pascale Bouillé, Flash Therapeutics, Toulouse, FR
Dr Carole Henry, Moderna, Cambridge, Massachusetts, USA
Prof. Houot is the Head of the Haematology Department at the University Hospital of Rennes (France). Prof. Houot’s research focuses on novel drug development and immunotherapy for the treatment of lymphoid malignancies. He has been the Principal Investigator (PI) of...
En savoir +Phil has 30 years of experience in the Pharmaceutical and Biotech industry having worked for small SME’s, larger pharmaceutical companies and CDMO’s. He has broad experience in manufacture of biologicals and NCE’s with experience in transfer of processes from R&D,...
En savoir +Philippe Bousso is an immunologist heading the Department of Immunology and the Dynamics of Immune Responses laboratory at Institut Pasteur. With the help of innovative imaging approaches, his research aims at understanding and manipulating immune responses in the context of...
En savoir +Celine ELIE-CAILLE obtained her Ph.D degree in enzymatic engineering from the University of Technology of Compiègne (UTC, France) in 2003. After a post-doctoral position at the BIOTEC Institute in Dresden (Germany) in 2004-2006 where she acquired skills in atomic force...
En savoir +From the beginning of my career in 2001 at the “Etablissement Français du Sang” (EFS, BFC, Besançon), I became interested in translational research and more particularly to modulate the T cells lymphocyte response, such as T cells involved in host-graft-tumor...
En savoir +Clinical trial assessor (PharmD, PhD) in the Early phase clinical trials Team, belonging to the Europe and Innovation Direction (DEI) of ANSM. DEI has two essential missions, the coordination of innovation, clinical research, and early and compassionate access policy but...
En savoir +Serial entrepreneur that combines strong strategic, technological and managerial experience with proven track record of deal-making and fund-raising. During his career he achieved together with its different teams to bring four drug candidates from research to the clinics (up to...
En savoir +Mathieu Guerriaud is a Doctor of Pharmacy (PharmD) and a Doctor of Science (PhD). He is an associate professor in pharmaceutical law, teaching at the Faculty of Health Sciences while working as a researcher in a law laboratory: the CREDIMI....
En savoir +Doctor in Immunology, researcher at and former director of the Autoimmunity-Transplantation-Inflammation research team at the INSERM-Univ Franche Comté-EFS Joint Research Unit 1098 RIGHT in Besançon (FR) for the last 10 years, Dr Perruche is now the founder and CEO of...
En savoir +Emmanuel Dequier is in charge of the French « Grand Défi Biomédicament » (National Challenge Biomedicines) whose objective is improving yields and control production costs. He previously held the position of Director of Research and Technology Platforms at Genopole, France's...
En savoir +Professor Olivier ADOTEVI completed his PhD training in immuno-oncology at 2006 at the Pierre & Marie Curie University, Paris and continued with a post-doctorate at Pasteur Institute Paris. To date, he is Professor of Clinical Immunology and thoracic oncology at...
En savoir +Associate Professor in Biochemistry & Molecular Biology in the Sciences University of Franche-Comté (Besancon, Fr), Philippe Dulieu founded RD-BIOTECH SAS in 2002, with 2 post-doc fellows specialized in molecular biology and antibody engineering, Jean-Luc Schlick and Jean-François Musard. Since 2002,...
En savoir +Director of the Hospital Clinic Institute of Hematology and Oncology, Clinical and Provincial Hospital of Barcelona, Spain. Professor of Medicine, University of Barcelona, Barcelona, Spain. Dr Urbano-Ispizua areas of expertise are stem cell transplantation, cellular immunotherapy and haemato-oncology. Dr Urbano-Ispizua...
En savoir +Mathilde Girard is a stem cell specialist, specialized in bioproduction and automation for cell therapy applications. After a PhD in Human Genetics she specialized in pluripotent stem cells applications at the I-Stem institute in Evry. She notably led a research...
En savoir +Carole Henry defended her PhD from the University of Franche-Comté in 2010. During that time while in the INSERM UMR645 (now UMR1098 RIGHT) she studied resistance to the anti-CD20 antibody, Rituximab, in B cell malignancies. In 2011, she started her...
En savoir +Since more than 20 years, I have been interested in the field of the T-cell response either after hematopoietic stem cell allo-transplantation or in the anti-tumor effect to modulate Graft versus Host disease (GvHD) or to initiate anti-tumoral effects (Graft...
En savoir +Dr Suman Mitra completed his degree in Microbiology and received his PhD in Human Immunology. He then performed his postdoctoral training at the National Heart, Lung, and Blood Institute (NHLBI) in Bethesda (USA). After several years working at the NIH...
En savoir +Marco Ruella, MD, is Assistant Professor of Medicine in the Division of Hematology/Oncology and the Center for Cellular Immunotherapies and Scientific Director of the Lymphoma Program at the Hospital of the University of Pennsylvania. His research focuses on the study...
En savoir +Marco Alessandrini, PhD, is the Chief Technical Officer for Antion Biosciences, leading the development and implementation of Antion’s proprietary technologies. After completing his studies, Marco worked five years in the private sector for Biotech and Pharma. He was initially involved...
En savoir +Pascale founded the company, Flash Therapeutics (FTX), in 2005. She provides her deep scientific expertise in the field of gene delivery and her breakthrough vision of gene therapies based on RNA. Pascale has led the successful transition of FTX from...
En savoir +Olivier DETANTE est professeur de Neurologie au CHU de Grenoble Alpes, au sein de l'Unité Neuro-Vasculaire, spécialisé dans la prise en charge des accidents vasculaires cérébraux (AVC). Depuis 15 ans, ses travaux de recherche translationnelle menés au Grenoble Institut des...
En savoir +CEO of Bone Therapeutics, Professor at the Lisbon University and Board of Directors and Executive Committee member for ARM and Board Member for Essenscia-Wallonie. President-Elect of ISCT from May 2022. Previously Chief Commercialization Officer and Chair of the ISCT Commercialization...
En savoir +Andreas Wallnöfer has over 25 years of experience in the pharmaceutical and biotech industry, including 12 years as a member of the F. Hoffmann-La Roche Pharma R&D Executive Leadership team. Prior to joining Jeito Capital as Partner and Investor in...
En savoir +Nathalie Labarriere is Inserm Research Director, in charge of the team 3 « Anti-tumor immunosurveillance and immunotherapy» and deputy director of the INCIT Unit (Immunology and new concepts in Immunotherapy). She started working in 1990 on tumor immunology in Nantes...
En savoir +He Huang, M.D., Ph.D., president of the First Affiliated Hospital, Zhejiang University School of Medicine; Director of Hematology Institution of Zhejiang University. Prof. Huang is also actively involved in and holds key positions in a number of professional organizations and...
En savoir +Chantal Pichon is Professor at the University of Orleans (France) and senior member of the Institut Universitaire de France, laureate of the Innovation chair. She carries out her research activities at the Centre de Biophysique Moléculaire (CNRS-Orléans) where she leads...
En savoir +Dr. Omid Veiseh, Ph.D., is an Assistant Professor and CPRIT Scholar in Cancer Research in the Department of Bioengineering at Rice University. He is a bioengineer and entrepreneur leading a cutting-edge research program aimed at developing and commercializing immunotherapy innovations...
En savoir +Dr. Julien Valton obtained his Ph.D. at the University Joseph Fourier in Grenoble, France, where he was trained as an enzymologist/biophysicist. He then joined the Yale School of Medicine to apply his knowledge to therapeutic research by investigating the mechanism...
En savoir +